Pharmacokinetics of amifostine: Effects of dose and method of administration

L. M. Shaw, H. S. Bonner, L. Schuchter, J. Schiller, R. Lieberman

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Findings of pharmacokinetic studies of amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) in animal models and in human cancer patients support the hypothesis that amifostine pharmacokinetics are nonlinear. The nonlinear pharmacokinetic behavior of amifostine suggests that administration of doses higher than 740 mg/m2 does not increase the amount of drug available due to urinary excretion of the excess parent drug and its metabolites. Although the intravenous formulation of amifostine is the only one currently used in the treatment of cancer patients, there is growing interest in the investigation of subcutaneous administration as a practical alternative. A pilot pharmacokinetic evaluation of subcutaneous administration of amifostine in 12 healthy male volunteers compared the relative bioavailability of 500 mg of amifostine administered subcutaneously with that of 200 mg/m2 given intravenously.

Original languageEnglish (US)
Pages (from-to)34-36
Number of pages3
JournalSeminars in Oncology
Volume26
Issue number2 SUPPL. 7
StatePublished - 1999

Fingerprint

Amifostine
Pharmacokinetics
Pharmaceutical Preparations
Biological Availability
Neoplasms
Healthy Volunteers
Animal Models
Parents

ASJC Scopus subject areas

  • Oncology

Cite this

Shaw, L. M., Bonner, H. S., Schuchter, L., Schiller, J., & Lieberman, R. (1999). Pharmacokinetics of amifostine: Effects of dose and method of administration. Seminars in Oncology, 26(2 SUPPL. 7), 34-36.

Pharmacokinetics of amifostine : Effects of dose and method of administration. / Shaw, L. M.; Bonner, H. S.; Schuchter, L.; Schiller, J.; Lieberman, R.

In: Seminars in Oncology, Vol. 26, No. 2 SUPPL. 7, 1999, p. 34-36.

Research output: Contribution to journalArticle

Shaw, LM, Bonner, HS, Schuchter, L, Schiller, J & Lieberman, R 1999, 'Pharmacokinetics of amifostine: Effects of dose and method of administration', Seminars in Oncology, vol. 26, no. 2 SUPPL. 7, pp. 34-36.
Shaw LM, Bonner HS, Schuchter L, Schiller J, Lieberman R. Pharmacokinetics of amifostine: Effects of dose and method of administration. Seminars in Oncology. 1999;26(2 SUPPL. 7):34-36.
Shaw, L. M. ; Bonner, H. S. ; Schuchter, L. ; Schiller, J. ; Lieberman, R. / Pharmacokinetics of amifostine : Effects of dose and method of administration. In: Seminars in Oncology. 1999 ; Vol. 26, No. 2 SUPPL. 7. pp. 34-36.
@article{88952656808245179fdd56dde14af06c,
title = "Pharmacokinetics of amifostine: Effects of dose and method of administration",
abstract = "Findings of pharmacokinetic studies of amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) in animal models and in human cancer patients support the hypothesis that amifostine pharmacokinetics are nonlinear. The nonlinear pharmacokinetic behavior of amifostine suggests that administration of doses higher than 740 mg/m2 does not increase the amount of drug available due to urinary excretion of the excess parent drug and its metabolites. Although the intravenous formulation of amifostine is the only one currently used in the treatment of cancer patients, there is growing interest in the investigation of subcutaneous administration as a practical alternative. A pilot pharmacokinetic evaluation of subcutaneous administration of amifostine in 12 healthy male volunteers compared the relative bioavailability of 500 mg of amifostine administered subcutaneously with that of 200 mg/m2 given intravenously.",
author = "Shaw, {L. M.} and Bonner, {H. S.} and L. Schuchter and J. Schiller and R. Lieberman",
year = "1999",
language = "English (US)",
volume = "26",
pages = "34--36",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 7",

}

TY - JOUR

T1 - Pharmacokinetics of amifostine

T2 - Effects of dose and method of administration

AU - Shaw, L. M.

AU - Bonner, H. S.

AU - Schuchter, L.

AU - Schiller, J.

AU - Lieberman, R.

PY - 1999

Y1 - 1999

N2 - Findings of pharmacokinetic studies of amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) in animal models and in human cancer patients support the hypothesis that amifostine pharmacokinetics are nonlinear. The nonlinear pharmacokinetic behavior of amifostine suggests that administration of doses higher than 740 mg/m2 does not increase the amount of drug available due to urinary excretion of the excess parent drug and its metabolites. Although the intravenous formulation of amifostine is the only one currently used in the treatment of cancer patients, there is growing interest in the investigation of subcutaneous administration as a practical alternative. A pilot pharmacokinetic evaluation of subcutaneous administration of amifostine in 12 healthy male volunteers compared the relative bioavailability of 500 mg of amifostine administered subcutaneously with that of 200 mg/m2 given intravenously.

AB - Findings of pharmacokinetic studies of amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) in animal models and in human cancer patients support the hypothesis that amifostine pharmacokinetics are nonlinear. The nonlinear pharmacokinetic behavior of amifostine suggests that administration of doses higher than 740 mg/m2 does not increase the amount of drug available due to urinary excretion of the excess parent drug and its metabolites. Although the intravenous formulation of amifostine is the only one currently used in the treatment of cancer patients, there is growing interest in the investigation of subcutaneous administration as a practical alternative. A pilot pharmacokinetic evaluation of subcutaneous administration of amifostine in 12 healthy male volunteers compared the relative bioavailability of 500 mg of amifostine administered subcutaneously with that of 200 mg/m2 given intravenously.

UR - http://www.scopus.com/inward/record.url?scp=0033029608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033029608&partnerID=8YFLogxK

M3 - Article

C2 - 10348258

AN - SCOPUS:0033029608

VL - 26

SP - 34

EP - 36

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 7

ER -